Dernières nouvelles pour AngioDynamics (NASDAQ:ANGO) Stock

ANGIODYNAMICS INC

AngioDynamics

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

AngioDynamics Inc

ANGO WORLD HOLDINGS INC by ANGO World Holdings, Inc.

Angold Resources Ltd Ordinary Shares

Lake Street analyst Frank Takkinen initiates coverage on AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy rating and announces Price Target of $24.

News

Price Target

Initiation

Analyst Ratings

ANGO

Lake Street Initiates Coverage On AngioDynamics with Buy Rating, Announces Price Target of $24

HC Wainwright &amp; Co. analyst Yi Chen reiterates AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and maintains $16 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $16 Price Target

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and raises the price target from $15 to $17.

Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $17

AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday posted a fourth-quarter 2025 adjusted loss of 3 cents per share, compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus for a per-share loss of 12 cents</a>.
Vascular system-focused medical device maker reported sales of $80.2 million, up 12.7% year over year, beating the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">consensus of $74.26 million</a>.
The report also revealed:
<ul class="wp-block-list">
<li>Med Tech net sales were $35.8 million, a 22% increase from $29.3 million in the prior-year period.</li>
<li>Growth was driven by Auryon sales during the quarter of $15.6 million, which increased 19.7%.</li>
<li>Mechanical Thrombectomy revenue, which includes AngioVac and AlphaVac, of $11.3 million, an increase of 44.7%.</li>
<li>NanoKnife disposable sales of $5.7 million, which increased 5.5% compared to the fourth quarter of fiscal 2024.</li>
<li>Med Device net sales were $44.4 million, representing a 6.2% increase from $41.8 million in the prior-year period.</li>
<li>The gross margin was 52.7%, down 161 basis points from the fourth <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46410588/angiodynamics-reports-strong-fiscal-year-2025-fourth-quarter-and-full-year-financial-results-conti" rel="noreferrer noopener">quarter of fiscal 2024</a>.</li>
<li>Absent the $1.6 million tariff impact in the quarter, gross margin would have been 54.7%.</li>
<li>Adjusted EBITDA was $3.4 million, compared to $1.5 million a year ago.</li>
<li>In 2025, AngioDynamics reported sales of $292.7 million, beating the management guidance <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44608672/medical-device-maker-angiodynamics-stock-jumps-on-better-than-expected-q3-earnings-upbeat-annual-guidance" rel="noreferrer noopener">of $285 million—$288 million</a>.</li>
</ul>
AngioDynamics CEO Jim Clemmer says the company is &#8220;profitable.&#8221; Its portfolio currently addresses some $10 billion in annual global market opportunities — up from $3 billion in 2021. 
&#8220;With our proven commercial momentum, multiple growth catalysts, and balance sheet strength, we&#8217;re exceptionally well-positioned for sustained value creation as we move into fiscal 2026,&#8221; Clemmer added.
Guidance: AngioDynamics expects its fiscal year 2026 net sales of $305 &#8211; $310 million, versus the consensus of $304.9 million.
The medtech company expects an adjusted loss between 35 and 25 cents per share. Compare that to the consensus loss of 23 cents per share.
For the full fiscal year 2026, the company expects a $4 million-$6 million impact from tariffs. For gross margin, pro forma adjusted EBITDA, and adjusted EPS, the low end of the respective ranges assumes the highest level of tariff impact, with the high end of the respective ranges assuming the lowest level of tariff impact.
Price Action: ANGO stock is up 5.3% at $10.14 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46410852/coreweave-commits-6-billion-to-us-ai-infrastructure-in-lancaster" target="_blank" rel="noreferrer noopener">CoreWeave Commits $6 Billion To US AI Infrastructure In Lancaster</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Health Care

Movers

Trading Ideas

General

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

WIIM

ANGO stock has given up its prior gain. AngioDynamics shares were trading higher after the company reported better-than-expected Q4 financial results and issued FY26 revenue guidance above estimates.

AngioDynamics shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 revenue guidance above estimates.

Fiscal Year 2026 Financial Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">
Current Guidance
(As of July 15, 2025)
</td>
<td colspan="1" rowspan="1">Tariff Guidance Impact</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">$305 - $310 million</td>
<td colspan="1" rowspan="1">Limited Impact</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Med Tech Net Sales Growth</td>
<td colspan="1" rowspan="1">12% - 15%</td>
<td colspan="1" rowspan="1">Limited Impact</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Med Device Net Sales Growth</td>
<td colspan="1" rowspan="1">Flat</td>
<td colspan="1" rowspan="1">Limited Impact</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">53.5% - 55.5%</td>
<td colspan="1" rowspan="1">Absent Tariffs: 55.0% - 56.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pro Forma Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$3.0 - $8.0 million</td>
<td colspan="1" rowspan="1">Absent Tariffs: $7.5M - $10.5M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">($0.35) - ($0.25)</td>
<td colspan="1" rowspan="1">Absent Tariffs: ($0.30) – ($0.25)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1">Positive for Full Year FY2026</td>
<td colspan="1" rowspan="1">Absent Tariffs: Up to +$5M</td>
</tr>
</tbody>
</table>
</figure>
Tariff Related Guidance Assumptions
For the full fiscal year 2026, the company expects a $4.0 - $6.0 million impact from tariffs. For gross margin, pro forma adjusted EBITDA, and adjusted EPS, the low end of the respective ranges assumes the highest level of tariff impact, with the high end of the respective ranges assuming the lowest level of tariff impact.

AngioDynamics Sees FY2026 Adj EPS $(0.35)-$(0.25) vs $(0.23) Est; Sees Sales $305M-$310M vs $304.858M Est

AngioDynamics Q4 2025 Adj. EPS $(0.03) Beats $(0.12) Estimate, Sales $80.158M Beat $74.256M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Telefonaktiebolaget L M (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $5.94 billion. 
• State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) is projected to report quarterly earnings at $2.38 per share on revenue of $3.35 billion. 
• Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) is expected to report quarterly earnings at $1.62 per share on revenue of $20.89 billion. 
• BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) is estimated to report quarterly earnings at $10.67 per share on revenue of $5.41 billion. 
• Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) is likely to report quarterly earnings at $1.41 per share on revenue of $20.74 billion. 
• JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) is projected to report quarterly earnings at $4.49 per share on revenue of $43.91 billion. 
• Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) is likely to report quarterly earnings at $1.74 per share on revenue of $4.83 billion. 
• AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $74.37 million. 
• Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) is estimated to report quarterly earnings at $0.52 per share on revenue of $24.70 billion. 
<h3>Companies Reporting After The Bell</h3>
• JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) is estimated to report quarterly earnings at $1.33 per share on revenue of $2.93 billion. 
• Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) is likely to report quarterly earnings at $1.90 per share on revenue of $494.93 million. 
• Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) is likely to report quarterly earnings at $2.02 per share on revenue of $3.96 billion. 
• Kestra Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMTS#NASDAQ">KMTS</a>) is projected to report quarterly loss at $0.53 per share on revenue of $15.69 million. 
• Hancock Whitney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWC#NASDAQ">HWC</a>) is estimated to report quarterly earnings at $1.35 per share on revenue of $374.15 million. 
• Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $321.86 million. 
• Castellum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTM#AMEX">CTM</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $13.45 million. 
• Calamos Glb Total (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGO#NASDAQ">CGO</a>) is estimated to report earnings for its third quarter. 
• Park Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKE#NYSE">PKE</a>) is likely to report earnings for its first quarter. 
• Rocky Mountain Chocolate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCF#NASDAQ">RMCF</a>) is projected to report earnings for its first quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ERIC

FULT

JBHT

KMTS

PNFP

RMCF

Earnings Scheduled For July 15, 2025

<h3>Gainers</h3>
<ul>
<li>Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) stock rose 7.9% to $6.53 during Monday's after-market session. The company's market cap stands at $274.7 million. </li>
<li>Atlantic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLN#NASDAQ">ATLN</a>) stock increased by 7.79% to $2.35. The company's market cap stands at $133.7 million. </li>
<li>AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) stock increased by 7.29% to $10.29. The market value of their outstanding shares is at $378.4 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock moved upwards by 7.23% to $0.68. The company's market cap stands at $2.7 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares moved upwards by 7.01% to $0.49. The market value of their outstanding shares is at $11.1 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares increased by 6.69% to $2.31. The market value of their outstanding shares is at $3.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Organogenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) shares fell 31.0% to $3.1 during Monday's after-market session. The company's market cap stands at $545.4 million. </li>
<li>MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares fell 20.48% to $5.4. The market value of their outstanding shares is at $981.4 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares declined by 14.07% to $0.6. The market value of their outstanding shares is at $25.2 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares fell 12.95% to $1.21. The company's market cap stands at $19.2 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock decreased by 11.86% to $0.42. The company's market cap stands at $10.6 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares declined by 8.4% to $0.4. The market value of their outstanding shares is at $16.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

ATLN

MDXG

NIVF

ORGO

QTRX

RANI

RLYB

SXTP

TLPH

VSEE

12 Health Care Stocks Moving In Monday's After-Market Session

AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-07-15. Here's what investors need to know before the announcement.
Analysts estimate that AngioDynamics will report an earnings per share (EPS) of $-0.12. 
Investors in AngioDynamics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.05, leading to a 9.58% drop in the share price on the subsequent day.
Here's a look at AngioDynamics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.13</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.04</td>
<td>-0.11</td>
<td>-0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>38.0%</td>
<td>-4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1752501742_0.png" alt="eps graph" />
<h3>Performance of AngioDynamics Shares</h3>
Shares of AngioDynamics were trading at $9.32 as of July 11. Over the last 52-week period, shares are up 28.1%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ANGO/earnings">To track all earnings releases for AngioDynamics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For AngioDynamics

Multi-center, multi-national study builds on existing U.S. PE Clearance and CE Mark to assess mechanical thrombectomy treatment and long-term functional outcomes in intermediate-risk PE patients across Europe
AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life, today announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute, intermediate-risk pulmonary embolism (PE).
The study follows the United States Food and Drug Administration (FDA) 510(k) clearance of the AlphaVac F1885 System for the treatment of PE in the United States in April 2024 and its CE Mark approval in Europe in May 2024. The RECOVER-AV trial is designed to evaluate the safety and efficacy of the AlphaVac F1885 System in support of its adoption in the Global market, as well as to assess long-term functional outcomes for patients following treatment.
The prevalence of PE in Europe is significant, particularly among hospitalized and older populations. An estimated 435,000 PE events occur annually in the six largest European Union (EU) countries1.
"The first patient enrollment in the RECOVER-AV trial marks an important step forward as AngioDynamics continues to grow its global clinical presence and commitment to evidence-based care," said Laura Piccinini, Senior Vice President/General Manager, Cardiovascular and International. "With AlphaVac already 510(k)-cleared in the U.S. and CE-marked in Europe for PE, we're investing in high-quality data focused on functional recovery and quality of life that will equip clinicians, payers, and patients with even greater confidence in the system's safe, effective performance and help broaden access to life-saving PE treatment across Europe and the wider global market."
The trial is enrolling patients with confirmed acute, intermediate-risk PE at up to 20 hospital-based sites in Europe, Canada, and Hong Kong. The primary safety endpoint is the incidence of adverse events by type and seriousness through 12 months. Patients will be followed for 12 months, with functional and quality-of-life outcomes assessed at 30 days and 12 months. Additional investigations, including Cardiac MRI and exercise testing, will provide a more comprehensive assessment of the long-term recovery of patients after mechanical thrombectomy with the AlphaVac MMA F1885 System.
The RECOVER-AV trial is led by co-Principal Investigators Erik Klok, MD, Professor of Medicine and Vascular Medicine Specialist at Leiden University Medical Center, and Andrew Sharp, MD, Professor of Interventional Cardiology at Mater Misericordiae Hospital and University College Dublin.
"Pulmonary embolism continues to be a leading cause of morbidity and mortality across Europe, underscoring the need for treatment strategies that are both safe and effective," said Professor Klok. "We're pleased to collaborate with AngioDynamics to generate evidence that could help shape future standards of care for intermediate-risk PE patients."

Biotech

AngioDynamics Announces It Has Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System For Treatment Of Acute Pulmonary Embolism

HC Wainwright &amp; Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and raises the price target from $15 to $16.

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $16

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Wednesday.
The Dow traded up 0.36% to 42,141.02 while the NASDAQ rose 0.90% to 17,607.06. The S&amp;P 500 also rose, gaining, 0.56% to 5,664.60.
Check This Out: <a href="https://www.benzinga.com/25/04/44604078/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks With Over 6% Dividend Yields</a>
Leading and Lagging Sectors Real estate shares rose by 0.1% on Wednesday.
In trading on Wednesday, information technology shares tumbled by 0.4%.
Top Headline
Private businesses in the U.S. added 155,000 jobs in March compared to a revised 84,000 gain in February and higher than market estimates of 105,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Innovation Beverage Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) shares shot up 207% to $1.52 after the company announced a distribution deal with a top national alcohol company to expand its reach in the US market.</li>
<li>Shares of AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>)got a boost, surging 9% to $10.55 after the company reported better-than-expected third-quarter sales results and raised its FY25 guidance above estimates.</li>
<li>ConnectM Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares were also up, gaining 123% to $1.1010 after the company announced it received a $1.60 per share buyout offer from 3 institutional investors.</li>
</ul>
Equities Trading DOWN
<ul>
<li>nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) shares dropped 24% to $21.50 after the company reported a fourth-quarter adjusted EPS miss. Additionally, Piper Sandler and Needham cut their respective price targets on the stock.</li>
<li>Shares of BingEx Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) were down 51% to $2.54.</li>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) was down, falling 49% to $0.1392 after the company announced it will delist its shares from Nasdaq capital market.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $71.21 while gold traded up 0.9% at $3,175.50.
Silver traded up 0.8% to $34.57 on Wednesday, while copper rose 0.2% to $5.0435.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.99%, Germany's DAX 40 dipped 1.33% and France's CAC 40 fell 0.77%. Spain's IBEX 35 Index fell 0.11%, while London's FTSE 100 fell 0.68%.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 gaining 0.28%, China's Shanghai Composite Index gaining 0.05%, Hong Kong's Hang Seng Index falling 0.02% and India's BSE Sensex gaining 0.78%.
Economics
<ul>
<li>U.S. mortgage applications fell by 1.6% in the week ending March 28.</li>
<li>Private businesses in the U.S. added 155,000 jobs in March compared to a revised 84,000 gain in February and higher than market estimates of 105,000.</li>
<li>New orders for US manufactured goods rose by 0.6% month-over-month for February compared to a revised 1.8% gain in January.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44605585/how-to-earn-500-a-month-from-conagra-brands-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

CNTM

NCNO

SYRA

Gold Moves Higher; US Private Sector Job Growth Tops Estimates

AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus for a per-share loss of 13 cents</a>.
The maker of medical Instruments and supplies reported sales of $72 million, up 9.2% year over year, beating the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">consensus of $70.3 million</a>.
Read Next: <a target="_blank" href="https://www.benzinga.com/25/04/44592342/apellis-pharmaceuticals-rare-kidney-disease-drug-under-fda-review-seeks-to-compete-novartis-recently-approved-drug" rel="noreferrer noopener">FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals</a>
Med Tech&#8217;s net sales were $31.3 million, up 22.2%, driven by strength across all product lines, including Auryon sales of $13.9 million, up 17.3%, AngioVac sales of $6.8 million, up 23.1%, AlphaVac sales of $3 million, up 161.4%, and NanoKnife disposable sales of $4.9 million, <a href="https://www.benzinga.com/pressreleases/25/04/b44602856/angiodynamics-reports-fiscal-year-2025-third-quarter-financial-results" target="_blank" rel="noreferrer noopener">which increased 16.2%</a>.
Med Device net sales were&nbsp;$40.7 million, almost flat year over year.
Gross margin for the third quarter of fiscal 2025 was 54.0%, up 290 basis points versus a year ago.
Adjusted EBITDA was $1.3 million, compared to a $3.6 million loss in the third quarter of fiscal 2024.
"As we look ahead, we are well positioned to deliver profitable growth going forward&#8230;With our improved operating leverage and strong balance sheet, we can continue to prudently invest to support high impact initiatives while remaining on track to hit our fiscal year 2026 profitability targets," said Jim Clemmer, president and CEO.
Guidance: AngioDynamics expects its fiscal-year 2025 net sales of $285 million to $288 million, representing growth of 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million, compared to prior guidance of $282 million—$288 million and a consensus of $284.91 million.
The outlook includes Med Tech net sales growth of 14% to 6%, compared with prior guidance of 12% to 15%. Med Device net sales are expected to be flat.
The gross margin is expected to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%
The company expects adjusted EBITDA of $4 to $5 million, an increase from prior guidance of $1 to $3 million, and compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal 2024
AngioDynamics forecasts fiscal year 2025 adjusted EPS loss of 31 cents to 34 cents, compared to prior loss guidance of 34 cents to 38 cents and consensus loss of 37 cents.
Price Action: ANGO stock is up 10.09% at $10.63 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/initiation/25/04/44592692/bwx-technologies-poised-for-growth-in-nuclear-power-medical-radioisotopes-says-analyst" target="_blank" rel="noreferrer noopener">BWX Technologies Poised For Growth In Nuclear Power, Medical Radioisotopes Says Analyst</a></li>
</ul>
Photo: Shutterstock/Pavel Kapysh

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

U.S. stocks were lower, with the Dow Jones index falling over 100 points on Wednesday.
Shares of Cognyte Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) rose sharply during Wednesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/CGNT">fourth-quarter financial results</a>.
Cognyte Software posted adjusted earnings of 3 cents per share, beating market estimates of 1 cent per share. The company's quarterly sales came in at $94.505 million versus expectations of $93.154 million.
Cognyte Software shares jumped 22.1% to $10.04 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares rose 13.7% to $10.98 after the company reported better-than-expected third-quarter sales results and raised its FY25 guidance above estimates.</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) gained 13.1% to $14.26.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares rose 12% to $41.99.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) shares surged 11.7% to $10.69.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 10.1% to $57.90.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) rose 9.8% to $7.04.</li>
<li>Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) surged 9.5% to $136.97.</li>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) gained 8.3% to $1.6250.</li>
<li>Allegiant Travel Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) rose 7.1% to $54.45. Raymond James analyst Savanthi Syth upgraded Allegiant Travel from Outperform to Strong Buy and lowered the price target from $125 to $90.</li>
<li>Studio City International Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 7% to $3.85.</li>
<li>Arcellx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) gained 5.9% to $64.28.</li>
<li>Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) shares rose 4.6% to $64.34.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose 3.8% to $248.24 ahead of quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44605585/how-to-earn-500-a-month-from-conagra-brands-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo via Shutterstock

ACLX

ALGT

CGNT

CIEN

COOP

CRWV

CYTK

GYRE

RDFN

SANA

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday

AngioDynamics shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 guidance above estimates.

AngioDynamics Expects 2025 Adjusted EPS Loss Of $(0.31)-$(0.34) Compared To Prior Guidance Of $(0.34)-$(0.38) And Consensus Of $(0.37)

Fiscal Year 2025 Financial Guidance
For fiscal year 2025:
<ul>
<li>The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.</li>
<li>The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.</li>
<li>The Company continues to expect Med Device net sales to be flat.</li>
<li>The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.</li>
<li>The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024. &nbsp;</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">Guidance Action</td>
<td colspan="1" rowspan="1">
Current Guidance
(As of Apr. 2, 2025)
</td>
<td colspan="1" rowspan="1">
Previous Guidance
(Issued on Jan. 8, 2025)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">$285 - $288 million</td>
<td colspan="1" rowspan="1">$282 - $288 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Med Tech Net Sales Growth</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">14 - 16%</td>
<td colspan="1" rowspan="1">12 - 15%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Med Device Net Sales Growth</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Flat (unchanged)</td>
<td colspan="1" rowspan="1">Flat</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">53 - 54%</td>
<td colspan="1" rowspan="1">52 - 53%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">$4.0 - $5.0 million</td>
<td colspan="1" rowspan="1">$1.0 - $3.0 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">($0.31) - ($0.34)</td>
<td colspan="1" rowspan="1">($0.34) - ($0.38)</td>
</tr>
</tbody>
</table>
</figure>

AngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M

AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.13) by 123.08 percent. This is a 118.75 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $72.00 million which beat the analyst consensus estimate of $70.30 million by 2.42 percent. This is a 4.23 percent decrease over sales of $75.18 million the same period last year.

Earnings Beats

AngioDynamics Q3 2025 Adj EPS $0.03 May Not Be Comparable To $(0.13) Estimate, Sales $72.00M Beat $70.30M Estimate

Press Releases

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

AngioDynamics to Host Virtual Cardiovascular Investor Event

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Comments

AngioDynamics

Actualités

Dernières nouvelles pour AngioDynamics (NASDAQ:ANGO) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL